Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<p>CAN-2409 + prodrug treatment reinvigorates tumor-retained, exhausted CD8<sup>+</sup> T cells, and tumor-experienced CD8<sup>+</sup> T cells, which egress tumors, have enhanced functionality. The effect of CAN-2409 + prodrug treatment on terminal exhaustion of CD8<sup>+</sup> T cells was assessed in the tumor using CX3CR1 as a marker coupled with the granzyme B expression. <b>A,</b> Representative flow cytometry plots for total, KG<sup>+</sup>, and KR<sup>+</sup> populations of total and TAA-specific (MC38 pentamer<sup>+</sup>) CD8<sup>+</sup> T cells and quantification are shown in <b>B</b>. <i>N</i> = 4–6 mice per group. Two-tailed <i>t</i> test, *, <i>P</i> < 0.05.</p>

Original publication

DOI

10.1158/2767-9764.28427833

Type

Publication Date

17/02/2025